MF
NVCR icon

Manchester Financial’s NovoCure NVCR Stock Holding History

Manchester Financial’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75
Closed -$10K – 452
2021
Q1 		$10K Sell
75
-75
-50% -$11.9K ﹤0.01% 432
2020
Q4 		$26K Hold
150
– – 0.02% 241
2020
Q3 		$17K Hold
150
– – 0.01% 256
2020
Q2 		$9K Hold
150
– – 0.01% 316
2020
Q1 		$10K Buy
+150
New +$11.9K 0.01% 291

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Financial's NVCR Position: Q2 2021 in Review

Manchester Financial sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 75 shares — an estimated $10K sold.

Manchester Financial first reported a position in NVCR in Q1 2020 and held it in 5 quarters. The position peaked at $26K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Manchester Financial reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Manchester Financial sold 75 NovoCure shares in Q2 2021, an estimated $10K.
  • Manchester Financial first reported a position in NovoCure in Q1 2020 and held it in 5 quarters.
  • Manchester Financial's NovoCure position peaked at $26K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.